Lupus Nephritis

Voclosporin’s Efficacy Confirmed for All Lupus Nephritis Biopsy Classes

Publish Date April 16, 2021

Add-on voclosporin improved complete renal response across all lupus nephritis biopsy classes, with the greatest benefit observed in pure class 3.

Cardiovascular Disease Risk Higher in Lupus Nephritis vs SLE Alone

Publish Date March 17, 2021

A comprehensive meta-analysis quantified the risks of several cardiovascular diseases in patients with systemic lupus erythematosus (SLE).

Pretreatment Predictor of Lupus Nephritis Remission Identified

Publish Date March 16, 2021

CD62L, a basophil activation marker, may be a noninvasive prognostic biomarker that can be used to treat patients with severe lupus nephritis.

Higher Initial Prednisone Dose for New-Onset LN Offers Superior Efficacy

Publish Date March 9, 2021

Patients with new-onset lupus nephritis achieve significantly higher rates of complete response at 1, 2, and 3 years if they receive a higher initial dose of prednisone for remission induction, a study found.

Venous Thromboembolism Risk in Lupus Nephritis Not Limited to Class 5

Publish Date March 5, 2021

This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators.

Mortality Highest for Asians, Hispanic/Latinos With Lupus

Publish Date March 1, 2021

Among patients with systemic lupus erythematosus, mortality is increased for minorities, especially Asian, Hispanic/Latina women

2019 EULAR/ACR Score Predicts Lupus Nephritis, Renal Flare Risk

Publish Date February 22, 2021

Study findings support the utility of the 2019 EULAR/ACR classification in everyday nephrology clinical practice.

Predictors of Kidney Failure in SLE Cases Identified

Publish Date February 18, 2021

Over 20 years, 8.4% of patients with lupus developed end-stage kidney disease, a study found.

Intensified B-Cell Depletion Protocol Effective in Lupus Nephritis

Publish Date February 16, 2021

Despite the disappointing results of randomized controlled trials such as LUNAR, targeting B cells remains an attractive option in patients with lupus nephritis, according to investigators.

Protein Marker May Predict ESKD Risk in Membranous Lupus Nephritis

Publish Date February 2, 2021

In a study, approximately one-third of patients with lupus membranous nephritis tested positive for the proteins exostosin 1/exostosin 2.